Related Experiment Video
Updated: Jan 17, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Optimizing KRAS Therapeutics for Non-Small Cell Lung Cancer
Jeong Uk Lim1,2, Marcelo V Negrao3, David S Hong1
1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;
Abstract:
This review examines the evolving treatment landscape for KRAS-mutant non-small cell lung cancer (NSCLC), along with the significance of KRAS mutations. The development of KRAS G12C inhibitors, such as sotorasib and adagrasib, has changed the treatment landscape for patients with KRAS-mutant NSCLC, overcoming the long-standing challenge of targeting KRAS. However, acquired resistance remains a major hurdle, along with the need for effective therapies for non-G12C KRAS mutations. Ongoing research into next-generation inhibitors and combination strategies aim to improve the clinical outcomes of KRAS-mutant NSCLC patients.
Insights
New KRAS G12C inhibitors offer hope for non-small cell lung cancer (NSCLC) patients. Research continues to address resistance and target other KRAS mutations for improved outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- KRAS mutations are key drivers in non-small cell lung cancer (NSCLC).
- Targeting KRAS has historically been challenging in cancer therapy.
- The emergence of KRAS G12C mutations presents a specific therapeutic target.
Purpose of the Study:
- To review the current treatment landscape for KRAS-mutant NSCLC.
- To discuss the impact of KRAS G12C inhibitors on NSCLC treatment.
- To identify challenges and future directions in targeting KRAS mutations in NSCLC.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of data on KRAS G12C inhibitors (sotorasib, adagrasib).
- Examination of resistance mechanisms and non-G12C KRAS mutation therapies.
Main Results:
- KRAS G12C inhibitors have transformed treatment for a subset of NSCLC patients.
- Acquired resistance to KRAS G12C inhibitors is a significant clinical challenge.
- Effective therapies for non-G12C KRAS mutations are still needed.
Conclusions:
- Targeting KRAS G12C has shown promise but resistance necessitates further innovation.
- Development of next-generation inhibitors and combination therapies is crucial.
- Improving outcomes for all KRAS-mutant NSCLC patients remains an active area of research.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...